Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway
Yingnan Zhao,1,2 Yanping Li,2 Qinhui Liu,1 Qin Tang,1,2 Zijing Zhang,1,2 Jinhang Zhang,1,2 Cuiyuan Huang,1,2 Hui Huang,1,2 Guorong Zhang,1,2 Jian Zhou,1,2 Jiamin Yan,1,2 Yan Xia,1,2 Zhiyong Zhang,1,2 Jinhan He1,2 1Department of Pharmacy, National Clinical Research Center for Geriatrics, West China H...
Main Authors: | Zhao Y, Li Y, Liu Q, Tang Q, Zhang Z, Zhang J, Huang C, Huang H, Zhang G, Zhou J, Yan J, Xia Y, He J |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-05-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/canagliflozin-facilitates-reverse-cholesterol-transport-through-activa-peer-reviewed-fulltext-article-DDDT |
Similar Items
-
Canagliflozin Attenuates Lipotoxicity in Cardiomyocytes by Inhibiting Inflammation and Ferroptosis through Activating AMPK Pathway
by: Wanqiu Zhang, et al.
Published: (2023-01-01) -
Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway
by: Mohamed S. Dabour, et al.
Published: (2023-08-01) -
Cholesterol Efflux: Does It Contribute to Aortic Stiffening?
by: Shutan Liao, et al.
Published: (2018-05-01) -
Cellular cholesterol efflux in heterozygotes for Tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size
by: Margaret E. Brousseau, et al.
Published: (2000-07-01) -
Different cellular traffic of LDL-cholesterol and acetylated LDL-cholesterol leads to distinct reverse cholesterol transport pathwayss⃞
by: Ming-Dong Wang, et al.
Published: (2007-03-01)